Source: https://submit.biopharmj.ru/ojs238/index.php/biopharmj/article/view/594
Timestamp: 2019-04-23 22:10:43+00:00

Document:
Мезенхимные стволовые/стромальные клетки (МСК), выделенные из тканей взрослого организма, представляют собой перспективный материал для регенеративной медицины. Однако клинические испытания, проводимые с применением этих клеток, не всегда дают положительный эффект. Причинами неэффективности клеточной терапии с использованием МСК могут быть как особенности донора и реципиента, так и несовершенства протоколов выделения, экспансии и криоконсервации клеток. Проведен сравнительный анализ функциональных характеристик МСК человека до и после криоконсервации с использованием разных протоколов. Обнаружено, что снижение дозы криопротектора способствует сохранению жизнеспособности и увеличению секреторной активности МСК.
Russell K. C., Phinney D. G., Lacey M. R., et al. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment / Stem Cell. 2010, V. 28. No. 4. P. 788 – 798.
Kalinina N. I., Sysoeva V. Y., Rubina K. A., et al. Mesenchymal Stem Cells in Tissue Growth and Repair / Acta Natur. Park Media Ltd. 2011, V. 3. No. 4. P. 30 – 37.
Zipori D. The stem state: mesenchymal plasticity as a paradigm / Curr. Stem Cell Res. Ther. 2014. V. 1. P. 95–102.
Kotova P. D., Sysoeva V. Y., Rogachevskaja O. A., et al. Functional expression of adrenoreceptors in mesenchymal stromal cells derived from the human adipose tissue / Mol. Cell Res. Elsevier BV. 2014. V. 1843. No. 9. P. 1899 – 1908.
Shi X., Zhang W., Yin L., et al. Vascular precursor cells in tissue injury repair / Transl. Res. 2017. V. 184. P. 77 – 100.
Phinney D. G. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy / J. Cell Biochem.2012. V. 113. No. 9. P. 2806 – 2812.
Han K. H., Kim A. K., Kim D. I. Therapeutic potential of human mesenchymal stem cells for treating ischemic limb diseases / Int. J. Stem Cell.2016. V. 9. No. 2. P. 163 – 168.
Joyce N., Annett G., Wirthlin, L., et al. Mesenchymal stem cells for the treatment of neurodegenerative disease / Regen. Med. 2010. V. 5. No. 6. P. 933 – 946.
Shao J., Zhang W., Yang T. Using mesenchymal stem cells as a therapy for bone regeneration and repairing / Biol. Res.2015. V. 48. No. 1. P. 62.
Maranda E. L., Rodriguez-Menocal L., Badiavas E. V. Role of mesenchymal stem cells in dermal repair in burns and diabetic wounds / Curr. Stem Cell Res. Ther. 2017. V. 12. No. 1. P. 61 – 70.
Liu S., Zhou J., Zhang X., et al. Strategies to optimize adult stem cell therapy for tissue regeneration / Int. J. Mol. Sci. 2016. V. 17. No. 6. P. E982.
Fong C. Y., Subramanian A., Biswas A., et al. Freezing of fresh wharton’s jelly from human umbilical cords yields high post-thaw mesenchymal stem cell numbers for cell-based therapies / J. Cell. Biochem. 2016. V. 117. No. 4. P. 815 – 827.
Ducar C., Smith D., Pinzon C., et al. NIAID HIV Vaccine Trials Network. Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal / J. Immunol. Meth. 2014. V. 409. P. 9 – 20.
Germann A., Oh Y. J., Schmidt T., et al. Temperature fluctuations during deep temperature cryopreservation reduce PBMC recovery, viability and T-cell function / Cryobiology.2013 V. 67. No. 2. P. 193 – 200.
Kalinina N., Kharlampieva D., Loguinova M., et al. Characterization of secretomes provides evidence for adipose-derived mesenchymal stromal cells subtypes / Stem Cell Res.2015. V. 6. P. 221.
Сагарадзе Г. Д., Григорьева О. А., Ефименко А. Ю. идр. Терапевтический потенциал секреторных компонентов мезенхимных стромальных клеток человека: проблема стандартизации / Биомед. хим. 2015. Т. 61. № 6. С. 750 – 759.
Efimenko A., Dzhoyashvili N., Kalinina N., et al. Adipose-Derived Mesenchymal Stromal Cells From Aged Patients With Coronary Artery Disease Keep Mesenchymal Stromal Cell Properties but Exhibit Characteristics of Aging and Have Impaired Angiogenic Potential / Stem Cell. Transl. Med. 2014. V. 3. No. 1. P. 32 – 41.
Hirashima M. Regulation of endothelial cell differentiation and arterial specification by VEGF and Notch signaling / Anat. Sci. Int.2009. V. 84. No. 3. P. 95 – 101.
Morishita R., Aoki M., Hashiya N., et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF) / Curr. Gene Ther.2014. V. 4. No. 2. P. 199 – 206.
Park Y. S., Kim G., Jin Y. M., et al. Expression of angiopoietin-1 in hypoxic pericytes: Regulation by hypoxia-inducible factor-2? and participation in endothelial cell migration and tube formation / Biochem Biophys Res. Commun. 2016. V. 469. No. 2. P. 263 – 269.
Duarte E. P., Curcio M., Canzoniero L. M., et al. Neuroprotection by GDNF in the ischemic brain / Grow. Fact. 2012. V. 30. No. 4. P. 242 – 257.
Pegg D. E. The relevance of ice crystal formation for the cryopreservation of tissues and organs / Cryobiology. 2010. V. 60. No. 3. P. 36 – 44.
Jang T. H., Park S. C., Yang J. H., et al. Cryopreservation and its clinical applications / Integr. Med. Res.2017. V. 6. No. 1. P. 12 – 18.
Windrum P., Morris T. C., Drake M. B., et al. EBMT Chronic Leukaemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres / Bone Marr. Transplant.2005. V. 36. No. 7. P. 601 – 603.
Best B. P. Cryoprotectant Toxicity: Facts, issues, and questions / Rejuven. Res.2015. V. 18. No. 5. P. 422 – 436.
Elliott G. D., Wang S., Fuller B. J. A review of the actions and applications of cryoprotective solutes that modulate cell recovery from ultra-low temperatures / Cryobiology. 2017. V. 76. P. 74 – 91.
Strobel J., Hohensee F., Kuta P., et al. Comparison of six different cryoprotective agents used for deep freezing and storage of CD34+ cells derived from cord blood and peripheral blood stem cell concentrates / Clin. Lab. 2017. V. 63. No. 3. P. 543 – 550.
Бондаренко Н. А., Лыков А. П., Ким И. И. идр. Влияние длительной криоконсервации на количество и функциональную активность стволовых/прогениторных клеток, полученных мобилизацией Г-КСФ от больных хронической сердечной недостаточностью / Патол. кровообр. и кардиохир. 2015. Т. 19. № 1. С. 90 – 94.
Lecchi L., Giovanelli S., Gagliardi B., et al. An update on methods for cryopreservation and thawing of hemopoietic stem cells / Transfus. Apher. Sci. 2016. V. 54. No. 3. P. 324 – 336.
Wang C., Xiao R., Cao Y. L., et al. Evaluation of human platelet lysate and dimethyl sulfoxide as cryoprotectants for the cryopreservation of human adipose-derived stem cells / Biochem. Biophys. Res. Commun. 2017. V. 491. No. 1. P. 198 – 203.
Yong K. W., Wan Safwani W. K., Xu F., et al. Cryopreservation of human mesenchymal stem cells for clinical applications: current methods and challenges / Biopres. Biobank. 2015. V. 13. No. 4. P. 231 – 239.
Mitrus I., Smagur A., Giebel S., et al. A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5 % dimethyl sulfoxide if compared to 10 % dimethyl sulfoxide containing medium / Cryobiology. 2013. V. 67. No. 3. P. 327 – 331.
Bourin P., Bunnell B. A., Casteilla L., et al. / Cytotherapy. 2013. V. 15. No. 6. P. 641 – 648.
Corwin W., Snyder K., Van Buskirk R., et al. Cryopreservation: Evolution of Molecular Based Strategies / Adv. Exp. Med. Biol. 2016. V. 951. P. 13 – 29.
M?ndez-Ferrer S., Michurina T., Ferraro F., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche / Nature. 2010. V. 466. No. 7308. P. 829 – 834.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.